Clinical trials: Dupilumab
Cholinergic Urticaria
Cholinergic Urticaria - Efficacy of Dupilumab
The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with cholinergic urticarial (CholU) who are symptomatic despite H1-antihistamine treatment (licensed dose).
- Trial name
- CHED (NCT03749148)
- Testing
- Dupilumab
- Where
- 8 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Charite University, Berlin, Germany
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
International Severe CRSwNP Registry 2024-2028
The objective of the study is to collect real-life data worldwide, which already have been collected in national databases, to merge the data and the knowledge with the focus of better care for the individual patients, more…
- Trial name
- INVENT (NCT06617754)
- Testing
- Biologic drugs
- Where
- Denmark
- Volunteers
- 3,000 people
- Sponsor
- Vibeke Backer
Cold Urticaria
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
Primary Objective: To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine…
- Trial name
- NCT04681729
- Testing
- Dupilumab SAR231893, Non sedating H1-antihistamine
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
Asthma Atopic, Asthma Severe Persistent Uncontrolled
Expression of TSLP Isoforms in Asthma
Asthma is a heterogeneous disease characterized by chronic airway inflammation, leading to variable airflow obstruction, bronchial hyperresponsiveness, excessive mucus secretion, and, consequently, structural airway remodeling.
- Trial name
- NCT07786870
- Testing
- No Intervention: Observational Cohort
- Where
- Poland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Atopic Dermatitis
Dupilumab Phase 4 Study
The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving…
- Trial name
- DRS (NCT03411837)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Northwestern University
Nasal Polyps
Complete Remission After Treatment With Biologics for Nasal Polyps
In this RCT the investigators randomize patients who are treated with biologic treatment (Nucala or Dupixent) due to nasal polyps and have controlled disease within the last year to either stop treatment og continue as a control…
- Trial name
- NCT07268313
- Testing
- DUPIXENT®, NUCALA®, Dupi discontinuation
- Where
- 6 sites in Denmark
- Volunteers
- 66 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
COVID-19
Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
This is a randomized, double-blind, placebo-controlled, superiority phase IIa trial to assess the safety and efficacy of dupilumab use in hospitalized patients with moderate to severe COVID-19 infection.
- Trial name
- SafeDrop (NCT04920916)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Asthma
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
- Trial name
- PANDA (NCT05347771)
- Testing
- Dupilumab
- Where
- 8 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma.
- Trial name
- NCT01854047
- Testing
- Dupilumab, ICS/LABA therapy, Salbutamol/albuterol
- Where
- 201 sites in United States, Argentina and 14 more
- Volunteers
- 776 people
- Sponsor
- Sanofi
Atopic Dermatitis
Dupilumab Skin Barrier Function Study in Atopic Dermatitis
Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis…
- Trial name
- BALISTAD (NCT04447417)
- Testing
- Dupilumab SAR231893
- Where
- 2 sites in United States, Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dermatitis Atopic
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss…
- Trial name
- PELISTAD-EX2 (NCT05983068)
- Testing
- dupilumab
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sanofi
Asthma
Dupilumab Compassionate Use Study
This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational…
- Trial name
- NCT03020810
- Testing
- Dupilumab
- Sponsor
- Sally E. Wenzel MD
Chronic Spontaneous Urticaria, Recurrent Angioedema
Dupilumab in Chronic Spontaneous Urticaria
The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with chronic spontaneous urticaria (CSU) who are symptomatic despite H1-antihistamine treatment.
- Trial name
- DUPICSU (NCT03749135)
- Testing
- Dupilumab
- Where
- 6 sites in Germany
- Volunteers
- 72 people
- Sponsor
- Charite University, Berlin, Germany
Atopic Dermatitis, Atopic Dermatitis Eczema
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported…
- Trial name
- DUPI REDUCE (NCT06004986)
- Testing
- Dupilumab
- Where
- 2 sites in Netherlands
- Volunteers
- 216 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
AERD - Aspirin Exacerbated Respiratory Disease
Effect of Dupilumab on Aspirin Intolerance
To test the efficacy of dupilumab in patients with AERD regarding the intolerance to salicylic acid after 6 months. This will be evaluated by oral drug provocation testing with low dose salicylic acid after 6 months of dupilumab…
- Trial name
- NCT04442256
- Testing
- Dupilumab
- Where
- Austria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Dermatitis, Atopic
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
- Trial name
- DUPLEX-AD (NCT06881251)
- Testing
- Dupilumab, JNJ-95475939
- Where
- 71 sites in United States, Argentina and 7 more
- Volunteers
- 256 people
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis
Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab
Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg twice a day (BID) in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing…
- Trial name
- NCT04306965
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tufts Medical Center
Asthma
A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service
Asthma is a common lung condition that causes occasional breathing difficulties and affects around 5.4 million people in the UK of all ages.
- Trial name
- REMISSION UK (NCT06261567)
- Testing
- Biologic treatment
- Where
- 4 sites in United Kingdom
- Volunteers
- 415 people
- Sponsor
- AstraZeneca
Asthma, Allergic
Study of REGN3500 and Dupilumab in Patients With Asthma
To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with placebo, on changes in inflammatory gene expression signatures in sputum induced after a bronchial allergen challenge (BAC) in adults with…
- Trial name
- NCT03112577
- Testing
- REGN3500, Dupilumab, Fluticasone propionate
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Sinusitis, Nasal Polyps
Biologics in Chronic Rhinosinusitis With Nasal Polyposis
The prevalence of Chronic Sinusitis with Nasal Polyps (CRSwNP) in the United States is estimated at roughly 4%, which equates to over 13 million Americans.
- Trial name
- CRSwNP (NCT06824649)
- Testing
- Biologic Agents
- Where
- 3 sites in United States
- Volunteers
- 504 people
- Sponsor
- Medical University of South Carolina